Printer Friendly

Detection and identification of occult hepatitis B virus infection among blood donors.

Introduction

Developing countries, such as India, which are endemic for hepatitis B pose a serious challenge for the blood banking community. The need of safe blood is of utmost importance for the repeat transfusion. Among the chronically transfused patients such as patients with thalassemia, the hepatitis B virus (HBV) prevalence as measured by HBV surface antigen (HBsAg) is 33%, whereas the prevalence in blood donor population is 1.2% [1] and posttransfusion prevalence of hepatitis has been observed to be 1%-1.8% in postsurgical transfusion. [2] Detection of HBV is primarily based on screening of hepatitis B surface antigen (HBsAg) as a serological marker of infection, which has been established globally for the diagnosis of acute or chronic HBV infections and for the screening of blood or organ donors in developing countries.[2,3] Emergence of mutant variants of Hepatitis B because of increased immunological pressure, by global immunization programs, or viral escapes in chronically infected patients have led to suboptimal performance of certain HBsAg assays. This is mainly because of natural variation and mutations in HBV S gene, which can induce HBsAg conformational changes. [4]

Occult HBV is the major contributor for transfusion transmitted HBV infection in highly endemic countries such as India. Hence, the need for individual donor nucleic acid test (ID-NAT) for HBV is necessary to circumvent the risk of missed positive cases during the window period, occult infections, and HBsAg assays that do not detect all known S mutants. Hepatitis B core antibody testing in countries endemic for HBV is also not suitable because of the high prevalence of individuals who harbor these antibodies. In addition, hepatitis B core antigen (anti-HBc) assay does distinguish between current and resolved HBV infections. [3]

Occult hepatitis B virus infection/carriage (OBI) is characterized by the presence of very low levels of HBV DNA in plasma and/or in liver, with undetectable HBsAg using the most sensitive commercial assays, with or without antibodies to antiHBc or hepatitis B surface antigen (anti-HBs) outside the pre-seroconversion window period. OBI prevalence varies between different geographic areas and populations according to HBV endemicity and HBV genotype. In Southeast Asia, where genotype B and C are prevalent, up to 90% of the population has evidence of past exposure to HBV. [5] A study was conducted to know the prevalence of OBI among blood donors and their serological and molecular characterization of NAT yield samples.

Materials and Methods

Study Design

All voluntary and replacement blood donors donating between February 2013 to August 2014 in the Department of Immunohematology and Blood Transfusion, Dayanand Medical College and Hospital, Ludhiana, Punjab were included in the study.

A total of 41,090 blood donor's samples were tested by ID-NAT apart from routine mandatory screening by ELISA (for HBsAg and anti-HIV, anti-HCV). Blood units that were HBsAg nonreactive but ID-NAT reactive (NAT yield) were further worked up with anti-HBc, anti-HBsAg, hepatitis "e" antigen (anti-HBe), viral load, and viral genotyping.

Donor Samples Studies

Serology

Anti-HBs screening was done by Biomerieux (HBsAg Ultra, France). Screening for antibody against anti-HBc total, anti-HBc IgM, anti-HBs, and anti-HBe was done by chemiluminescence immunoassays (CLIA).

ID-NAT

All the samples were tested individually by Procleix [R] Utrio Plus [R] Assay (Novartis Emeryville, CA). It is a transcription-mediated amplification (TMA)-based screening for the simultaneous, single tube detection. The entire test takes place in a single tube and involves three steps (1) target capture, (2) target amplification by TMA, (3) detection of the amplification products with chemiluminescent probes by the hybridization protection assay. Finally, the dual kinetic assay simultaneously detects the internal control and the viral RNA or DNA.

All three assays incorporate internal control to validate each reaction. ID-NAT is a multiplex assay that provides simultaneous detection of HIV, HCV RNA, and HBV DNA. Samples found reactive initially in the Utrio plus Assay were later retested by using the multiplexed protocol.

Individual Donor Procleix [R] Ultrio Plus [R] Assay is a sensitive screening assay available. The analytic sensitivity of Procleix [R] Ultrio Plus [R] Assay (95% detection limit for routine testing) for HIV-1 is 27.6 IU/mL, for HCV is 3.1 IU/mL, and for HBV is 2.1 IU/mL. [6]

Viral Load and Genotyping

HBV DNA quantification, amplification, and sequencing were determined by quantitative real-time PCR (polymerase chain reaction) by Roche Cobas Ampliprep-TaqMan Assay. Linear reporting range of the assay was 20-1.7 x [10.sup.8] IU/mL. Conversion factor used for 1 IU/mL was 5.82 copies/mL. HBV genotyping was done on reactive cases if the value was > 2000 copies/mL and distinguishes A-H genotypes.

Result

From the initial screening of 41,090 samples, 29 were found reactive for HBV DNA (NAT yield). Among these 29 NAT yields, 24 were individual NAT yield, 4 were HBV-HCV NAT co-yield, and 1 was HBV-HIV NAT co-yield; therefore, HBV NAT yield rate is 1 in 1,417.

A total of 24 HBV individual NAT yield samples were further tested for OBI and 5 samples of NAT co-yield could not be further classified because CLIA data were not available because of insufficient quantity of sample. Mean age distribution of donors of these 24 NAT yield was 39.2 years (25 to 58 years). All donors were male, 10 of 24 (41.6%) were voluntary and 14 of 24 (58.4%) were replacement.

A total of 11 samples were reactive for anti-HBc only, 3 samples carried both anti-HBc and anti-HBs, yielding a total of 14 samples that were classified as OBI and one sample was reactive for anti-HBs only. Nine samples did not have any serological marker owing to incomplete antibody, and they remained unclassified, as window period infection could not be excluded. Two HBV-NAT yield samples of genotype D, one with a window period and the second being an OBI had a high viral load that was detected by qPCR. Twenty-four of the HBV-NAT yields could be grouped in different stages of infections according to the supplement HBV serology results as shown in Table 1. Of the residual confirmed HBV-NAT yields, 8 (33.3%) were classified as window period, 1 (4.2%) as late acute window period or early recovery stage, 1 (4.2%) as anti-HBs breakthrough or abortive infection, and 14 (58.3%) as OBI. Table 2 summarized the proportion and rate of different acute and chronic HBV infection stages.

Discussion

To assess the safety of the blood supply as it pertains to the risk of transmitting HBV to the recipients requires comprehensive understanding of virus-host relationship, the natural history of this disease, and the serological changes that follow exposure to the virus.

HBsAg is the first hepatitis B serological marker to be detected in the blood following the HBV infection. Screening of blood for HBsAg has reduced the incidence of post-transfusion hepatitis but HBV still remains the major source of TTIs in India. HBV has a slow doubling time of 2.7 days resulting in slow increase in the viral load, hence the longest window period from infection to detection and even NAT testing. [7] The introduction of routine NAT testing of blood donation has resulted in a decrease in the rate of transfusion-transmitted viral infection by the interdiction of donors in serological window period; although NAT testing is being adopted more widely, it has become clear that challenges still remain. [8] In India, because of relatively high HBsAg positivity of 1%-2% in donor population, 10%-30% anti-HBc prevalence, the major HBV type being genotype D followed by A and C, with genotype D and A documented to remain at low viral load, and association of HBV genotype D with high OBI, which is characterized by fluctuating low viral load necessitate the need of NAT testing. [9, 10]

It is generally accepted that the diagnosis of infection by HBV is based on the presence of the HBsAg in the blood stream. However, screening of blood bank donors for HBsAg does not totally eliminate the risk of HBV infection through blood transfusion, as the absence of this marker in the serum does not exclude the presence of HBV DNA. It is possible that, donors with OBI, who lacked detectable HBsAg but whose exposure to HBV infection was indicated by a positive anti-HBc and HBV DNA, are a potential source of HBV infection. [11,12]

In this study, additional testing, both NAT and serology and where appropriate, testing of follow-up samples, indicated that the 14 NAT-only yield samples were from donors with an OBI, 9 samples were from donors in a window period, and 1 with abortive infection. HBV activity might be impaired by other infectious agents in cases with coinfection such as HCV. HCV "core" protein strongly inhibits HBV replication, and OBI shows the highest prevalence in patients infected with HCV. [13] Even in our study, four samples were NAT co-yield with HCV and one with HIV; therefore, there is a requirement for ID-NAT testing in such region that is very sensitive for the detection and identification of HBV DNA.

Several recent studies have shown that blood products from donors with an OBI can result in transfusion-transmitted HBV. [14,15] HBV transmission can occur even in the presence of low levels of anti-HBs (<200 IU/L). [16] The prevalence of OBI previously reported among blood donors in Asia is 1:570-1:8,628 in China, 1:3,248 in Hong Kong, 1:894-1:1,029 in Taiwan, and 1:832 in Thailand. [R] A previous study from Delhi, tried to assess the ability of ID-NAT to detect OBI in the blood donors. Of the 18 NAT yields, anti-HBc was nonreactive in 6 out of 18 NAT yields, reflecting potential infectious donations that would escape detection by HBsAg and anti-HBc screening. [17]

Many studies were conducted in HBsAg-negative samples among blood donors in our country but almost all have studied [18,19] the seroprevalance of antibody to core antigen (HBc). The incidence of anti-HBc is being reported from 30.2% to 8.4%. Anti-HBc is long-lasting, which is detectable later than HBsAg but associated with lower rates of transfusion transmission in the absence of HBsAg. Application of anti-HBc as a screening modality in blood donors is largely debated because of its association with high discard rate.

Transfusion-associated HBV continues to be a significant problem in our country. Its prevalence is estimated at approximately 1.5% in postsurgical blood transfusion recipients or more in patients who had multiple transfusions in India. [20] Our study raises serious concerns regarding the safety of the blood supply in our community, even after donor screening for HBsAg and NAT. In conclusion, transfusion-transmitted infections including HBV have been a major concern in transfusion medicine. Screening of blood for HBsAg has reduced the incidence of posttransfusion hepatitis, but HBV still remains the major source of transfusion-transmitted infection in India.

HBV transmission by blood and blood products despite HBsAg screening is mainly because of prevalence of occult hepatitis B infection among donors. In a developing country like India with a high seroprevalence of HBV infection, combination of at least two tests would help us to improve the transfusion safety. The introduction of the NAT test in regions would add an extra layer of safety to the blood supply by interdicting samples from donors with an OBI.

Conclusion

Blood products from donors with OBI carry a high risk of HBV transmission by transfusion. Because of multiple antigens and antibodies present in blood in response to HBV infection, at present there is no single test to detect the infection. In a developing country like India, with a high seroprevalence of HBV infection, combination of at least two tests would help us to improve the transfusion safety.

DOI:10.5455/ijmsph.2016.29022016399

References

[1.] Singh H, Pradhan M, Singh RL, Phadke S, Naik SR, Aggarwal R, et al. High frequency of hepatitis B virus infection in patients with beta-thalassemia receiving multiple transfusions. Vox Sang 2003;84(4):292-9.

[2.] Singh B, Verma M, Verma KJ. Markers for transfusion-associated hepatitis in North Indian blood donors: prevalence and trends. Jpn J Infect Dis 2004;57(2):49-51.

[3.] Bhattacharya P, Chandra PK, Datta S, Banerjee A, Chakraborty S, Rajendran K, et al. Significant increase in HBV, HCV, HIV and syphilis infections among blood donors in West Bengal, Eastern India 2004-2005: exploratory screening reveals high frequency of occult HBV infection. World J Gastroenterol 2007;13(27):3730-3.

[4.] Perazzo P, Equibar N, Gonzalez RH, Nusblat AD, Cuestas ML. Hepatitis B virus (HBV) and S-escape mutants: from the beginning until now. J Hum Virol Retrovirol 2015;2(3):00046.

[5.] Candotti D, Lin CK, Belkhiri D, Sakuldamrongpanich T, Biswas S, Lin S, et al. Occult hepatitis B infection in blood donors from South East Asia: molecular characterization and potential mechanisms of occurrence. Gut 2012;61(12):1744-53.

[6.] Grabarczyk P, Drimmelen HV, Kopacz A, Gdowska J, Liszewski G, Piotrowski D, et al. Head-to-head comparison of two transcription-mediated amplification assay versions for detection of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus Type 1 in blood donors. Transfusion 2013;53(10 Pt 2):2512-24.

[7.] Kleinman SH, Lelie N, Busch MP Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009;49(11):2454-89.

[8.] Roth WK, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, et al. International survey on NAT testing of blood donations; Expanding implementation and yield from 1999 to 2009. Vox Sang 2012; 102(1):82-90.

[9.] Shyamala V. Factors in enhancing blood safety by nucleic acid technology testing for human immunodeficiency virus, hepatitis C virus and hepatitis B virus. Asian J Transfus Sci 2014;8(1):13-8.

[10.] Lin KT, Chang CL, Tsai MH, Lin KS, Saldanha J, Hung CM. Detection and identification of occult HBV in blood donors in Taiwan using a commercial, multiplex, multi-dye nucleic acid amplification technology screening test. Vox Sang 2014;106(2):103-10.

[11.] Makroo RN, Chowdhry M, Bhatia A, Arora B. Rosamma NL. Hepatitis B core antibody testing in Indian blood donors: a double edged sword! Asian J Transfus Sci 2012;6(1):3-10.

[12.] Seo DH, Whang DH, Song EY, Han KS. Occult hepatitis B virus infection and blood transfusion. World J Hepatol 2015;7(3):600-6.

[13.] Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007;46(1):160-70.

[14.] Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP. Anti-HBs positive occult hepatitis B virus carrier blood infection in two transfusion recipients. J Hepatol 2008;48(6):1022-5

[15.] Liu CJ, Chen DS, Chen PJ. Epidemology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol 2006;36(Supp 1):S33-44.

[16.] Taira R, Satake M, Momose S, Hino S, Suzuki Y, Murokawa H, et al. Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan. Transfusion 2013;53(7): 1393-404.

[17.] Doda V, Arora S, Kirtania T. Serological characterization of occult hepatitis B virus infection among blood donors in India. Transfus Apher Sci 2014;51(2):162-7.

[18.] Chaudhuri V, Tayal R, Nayak B, Achyarya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology 2004;127(5):135-7.

[19.] Dhawan HK, Marwhaha N, Sharma RS, Chawla Y, Thakrai B, Saluja K, et al. Anti-HBc screening in Indian blood donors: still an unresolved issue. World J Gastroenterol 2008;14(34):5327-30.

[20.] Chaudhuri V, Nanu A, Panda SK, Chand P. Evaluation of serologic screening of blood donors in India reveals a lack of correlation between anti-HBc titer and PCR-amplified HBV DNA. Transfusion 2003;43(10):1442-8.

Rajesh Kumar, Amarjit Kaur, Sonia Gupta, Ramneek Locham, Gurkiran Kaur

Department of Pathology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.

Correspondence to: Gurkiran Kaur, E-mail: gurkirankaur10@yahoo.com

Received February 29, 2016. Accepted March 9, 2016
Table 1: Triplicate repeat NAT and supplemental test results in
24 HBV NAT yields (classified in different infection stages)

           Case Donor status             Blood bank NAT result

        Sex   Type   Tube IR             3X Replicate
Sr.
no.                              Tube     Bag    dHIV    dHCV    dHBV

1        M     R        R         1/3     2/3     0/3     0/3     3/3
2        M     V        R         3/3     3/3     0/3     0/3     3/3
3        M     V        R         3/3     3/3     0/3     0/3     3/3
4        M     R        R         3/3     3/3     0/3     0/3     3/3
5        M     R        R         3/3     3/3     0/3     0/3     3/3
6        M     V        R         2/3     1/3     0/3     0/3     2/3
7        M     R        R         2/3     2/3     0/3     0/3     2/3
8        M     R        R         2/3     3/3     0/3     0/3     3/3
9        M     V        R         3/3     3/3     0/3     0/3     3/3
10       M     V        R         1/3     1/3     0/3     0/3     1/3
11       M     R        R         1/3     1/3     0/3     0/3     1/3
12       M     R        R         3/3     3/3     0/3     0/3     3/3
13       M     R        R         3/3     3/3     0/1     0/1     1/3
14       M     V        R         3/3     0/3     0/3     0/3     2/3
15       M     V        R         1/3     3/3     0/3     0/3     3/3
16       M     R        R         2/3     2/3     0/3     0/3     2/3
17       M     R        R         2/3     1/3     0/3     0/3     1/3
18       M     V        R         2/3     2/3     0/3     0/3     2/3
19       M     R        R         1/3     2/3     0/3     0/3     2/3
20       M     V        R         3/3     3/3     0/3     0/3     3/3
21       M     R        R         3/3     3/3     0/3     0/3     3/3
22       M     R        R         2/3     1/3     0/3     0/3     1/3
23       M     V        R         1/3     3/3     0/3     0/3     3/3
24       M     R        R         2/3     2/3     0/3     0/3     2/3

      Supplemental viral load and serology (CLIA) results

      VLqPCR    Geno-   HBsAg    a-HBc    a-HBc   a-HBs   a-HBe
Sr.   (IU/mL)   type            (Total)   (IgM)
no.

1      2161       D      NR       NR       NR      NR      NR
2       39               NR       NR       NR      NR      NR
3       94               NR       NR       NR      NR      NR
4       ND               NR       NR       NR      NR      NR
5       ND               NR       NR       NR      NR      NR
6       ND               NR       NR       NR      NR      NR
7       14               NR       NR       NR      NR      NR
8       ND               NR       NR       NR      NR      NR
9       ND               NR        R        R      NR       R
10      ND               NR       NR       NR       R      NR
11      ND               NR        R       NR      NR       R
12      21               NR        R       NR      NR       R
13      <10              NR        R       NR      NR       R
14      ND               NR        R       NR      NR       R
15      ND               NR        R       NR      NR       R
16      31               NR        R       NR      NR       R
17      ND               NR        R       NR      NR      NR
18      17               NR        R       NR      NR      NR
19      NA               NR        R       NR      NR      NR
20      10               NR        R       NR      NR      NR
21     2,434      D      NR        R       NR      NR      NR
22      ND               NR        R       NR       R      NR
23      ND               NR        R       NR       R      NR
24      <10              NR        R       NR       R      NR

      Supplemental viral load and serology (CLIA) results

      Classification HBV infection
Sr.
no.

1
2
3
4     Window period
5
6
7
8
9     Late acute
10    Anti-HBs breakthrough
11
12    OBI with a-Hbe and
13    without a-HBs (low level
14    carrier, early convales-
15    cent period, chronic;
16    potentially infectious)
17
18    OBI without a-Hbe and
19    a-HBs (chronic; potentially
20    infectious)
21
22    OBI with a-HBs (late
23    phase) previous infection
24    with immunity

NAT, nucleic acid test; CLIA, chemiluminescence immunoassays;
HBsAg, hepatitis B surface antigen; HBe, hepatitis "e" antigen;
HBV, hepatitis B virus; HIV, human  immunodeficiency virus; NA,
sample not available; D, genotype D; ND, not detectable; OBI,
occult HBV infection; M, male; a, anti; V/R, voluntary/
replacement.

Table 2: HBV infection rate

HBV yield rates

Classification                    n       Rate      % Age

Pre-HBsAg WP                      09    1/4,565     37.5
aHBs breakthrough                 01    1/41,090     4.2
OBI aHBs (negative)               11    1/3,735     45.8
OBI aHBs (positive)               3     1/13,696    12.5
Total classified HBV NAT yield    24    1/1,712      100

HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; OBI,
occult HBV infection; NAT, nucleic acid test.
COPYRIGHT 2016 Association of Physiologists, Pharmacists and Pharmacologists
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Kumar, Rajesh; Kaur, Amarjit; Gupta, Sonia; Locham, Ramneek; Kaur, Gurkiran
Publication:International Journal of Medical Science and Public Health
Geographic Code:9INDI
Date:Oct 1, 2016
Words:3425
Previous Article:An assessment of the functioning of the village health sanitation and nutrition committee in the rural areas of Kamrup district, Assam.
Next Article:Study of changes in red blood cell indices and iron status during three trimesters of pregnancy.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters